Spotlights on Inspiring New Collaborative Approaches to Discovery and Development of Treatments and Cures
University of Maryland researchers have discovered that seemingly identical cells can use different protein molecules to carry out the same function in an important cellular process. The scientists named this newly discovered variability “functional mosaicism,” and it has significant implications for the development of therapeutic treatments, which are often designed to target a specific molecule, or a gene that produces a specific molecule.
Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that it has appointed brain tumor expert E. Antonio ‘Nino’ Chiocca, M.D., Ph.D., Harvey W. Cushing Professor of Neurosurgery, Harvard Medical School Neurosurgeon-in-Chief and Chairman, Department of Neurosurgery, Brigham and Women’s Hospital to its scientific advisory board. ITI is currently applying its investigational UNITE™ platform in immuno-oncology, particularly for virally driven brain cancers, and Dr. Chiocca’s extensive expertise in this field will be instrumental to these efforts.
By invitation only: For questions email BHI@BioHealthInnovation.org
Gaithersburg, MD
Are you an experienced biohealth entrepreneur seeking new opportunities in the BioHealth Capital Region? BioHealth Innovation is developing a database of experienced industry personnel willing to work in potential C-suite positions with our university and startup partners. If you would like to have your contact information and vita included in this database for their review and have not done so already, please submit your information to BHI via this form.
Congress and the Trump administration are considering proposals to reduce the price of drugs, but there is a strong causal link between current drug prices and revenues on one hand and future drug research and treatments on the other. Policymakers should keep in mind this trade-off between short-term affordability and long-term innovation: Reducing drug revenues today will lead to a decline in future R&D and a decrease in the number of new drug discoveries.
708 Quince Orchard Road, Gaithersburg, Maryland
Three move-in ready laboratory/office modules; each approximately 1,200 RSF with communal services and amenities designed to facilitate collaboration.
- Fully fit out laboratory space
- Office space includes one furnished office and two workstations
- Communal space includes reception/lobby area, pantry, conference rooms, IT closet, autoclave, glass wash, and ice maker
- BioHealth Innovation will provide their Startup and Entrepreneur-in-Residence programs and various supporting services to guide and facilitate the growth of early-stage companies
- FitLab, Alexandria’s state-of-the-art fitness center, is located in close proximity
Viewed simply by dollar value, the value of mergers-and-acquisitions (M&A) activity appeared to be zooming in the first half of this year: Statistics compiled for GEN by Informa Pharma Intelligence’s Medtrack and Strategic Transactions services showed a total $184.05 billion worth of deals for which values were disclosed, up nearly 38% from the $133.73 billion recorded for January–June 2018.
Each Cyclops had a single eye because, legend has it, the mythical giants traded the other one with the god Hades in return for the ability to see into the future. But Hades tricked them: the only vision the Cyclopes were shown was the day they would die. They carried this knowledge through their lives as a burden—the unending torture of being forewarned and yet having no ability to do anything about it.
Two more Bay Area companies hit unicorn valuations of $1 billion or more at the end of the week as part of more than $550 million in funding that was disclosed in the region. Here’s more on that and other venture news.